Establishment and validation of serum lipid-based nomogram for predicting the risk of prostate cancer

BMC Urology

Table 1 Patient demographics and clinical characteristics of the Training group and Validation group

Demographic characteristics	Total	Training group		Validation group		P-value
Demographic characteristics	Total	No cancer, n(%)	PCa, n(%)	No cancer, n(%)	PCa, n(%)	P-value
Age (years)						0.394
< 60	70	18	28	11	13
≥ 60	478	192	146	76	64
BMI (kg/m ² )						0.53
< 18.5	25	5	10	5	5
[18.5, 23.9)	193	79	57	29	28
≥ 23.9	330	126	107	53	44
PSA (ng/ml)						0.292
< 4	246	132	46	53	15
≥ 4	302	78	128	34	62
f/t PSA						0.111
< 0.16	239	68	91	30	50
≥ 0.16	309	142	83	57	27
PSAD						0.466
< 0.15	307	143	76	59	29
≥ 0.15	241	67	98	28	48
TC (mmol/L)						0.278
< 5.69	471	177	149	74	71
≥ 5.69	77	33	25	13	6
TG (mmol/L)						0.843
< 1.7	424	175	123	72	54
≥ 1.7	124	35	51	15	23
HDL (mmol/L)						0.53
< 1.55	485	194	148	80	63
≥ 1.55	63	16	26	7	14
LDL (mmol/L)						0.805
< 3.37	424	181	115	69	59
≥ 3.37	124	29	59	18	18
apoA-1 (g/L)						0.501
< 1.7	526	206	164	83	73
≥ 1.7	22	4	10	4	4
apoB (g/L)						0.815
< 1.55	228	93	68	35	32
≥ 1.55	320	117	106	52	45
DRE						0.155
Negative	367	149	101	73	44
Positive	181	61	73	14	33
TRUS						0.69
Negative	339	152	95	52	40
Positive	209	58	79	35	37

BMI, Body Mass Index; PSA, Prostate specific antigen; TC, total cholesterol; TG, Triglyceride; HDL, high-density lipoprotein; LDL, Low-density lipoprotein; apoA-1, apoprotein A-1; apoB, apoprotein B; DRE, digital rectal exam; TRUS, Transrectal Ultrasonography;

ISSN: 1471-2490